Veverimer(Veverimer) - _专利_临床

概要

基本信息

药物类型

聚合物

别名

Alezuris

靶点-

作用方式-

作用机制

粘合剂

治疗领域

内分泌与代谢疾病泌尿生殖系统疾病

在研适应症-

非在研适应症

酸中毒慢性肾病

原研机构

Tricida, Inc.

在研机构

Renibus Therapeutics, Inc.

非在研机构

Tricida, Inc.

权益机构

Tricida, Inc.

Renibus Therapeutics, Inc.

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看时间轴

结构/序列

分子式C14H29Cl2N3

InChIKeyBVCUKLLDEVBJBT-UHFFFAOYSA-N

CAS号2099678-27-8

关联

4

项与 Veverimer 相关的临床试验

NCT03710291

/ Terminated临床3期

A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects With Metabolic Acidosis

The purpose of this study is to evaluate the effect of TRC101 on the progression of chronic kidney disease (CKD) and to evaluate the safety profile of TRC101 in CKD patients with metabolic acidosis.

开始日期2018-11-20

申办/合作机构

Tricida, Inc.

NCT03390842

/ Completed临床3期

A Blinded, Placebo-Controlled Extension to Study TRCA-301 to Evaluate the Long-term Safety and Durability of Effect of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis

This study is a 40-week, blinded, placebo-controlled extension of Study TRCA-301 (NCT03317444). Eligible subjects who complete the 12-week treatment period in Study TRCA-301 have the option to participate in this extension study evaluating the long-term safety and durability of effect of TRC101 in subjects with non-dialysis dependent chronic kidney disease and metabolic acidosis. Eligible subjects will be treated with TRC101 or placebo once daily (QD) on an out-patient basis for the subsequent 40 weeks. Subjects will continue to receive the same blinded treatment (TRC101 or placebo) that they received in Study TRCA-301.

开始日期2017-12-20

申办/合作机构

Tricida, Inc.

NCT03317444

/ Completed临床3期

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TRC101 in Subjects With Chronic Kidney Disease and Metabolic Acidosis

This is a multicenter, double-blind, placebo-controlled, parallel-design study. The study will enroll approximately 210 adult male and female subjects with stage 3 or 4 chronic kidney disease and metabolic acidosis. The study dosing (TRC101 or placebo) will continue for 12 weeks once daily.
The maximum study duration is anticipated to be up to 16 weeks.

开始日期2017-09-26

申办/合作机构

Tricida, Inc.

100 项与 Veverimer 相关的临床结果

登录后查看更多信息

100 项与 Veverimer 相关的转化医学

登录后查看更多信息

100 项与 Veverimer 相关的专利（医药）

登录后查看更多信息

25

项与 Veverimer 相关的文献（医药）

2024-05-01·Current Opinion in Nephrology & Hypertension

A basic solution for a complex problem: does treatment of metabolic acidosis slow CKD progression?

Review

作者: Arora, Nayan ; Freidin, Natalie ; Bodker, Kevin

Purpose of this reviewMetabolic acidosis is frequently encountered in patients with chronic kidney disease (CKD), with increasing prevalence as kidney function worsens. Treating electrolyte disturbances is the sine qua non of Nephrologists, and alkali therapy to normalize serum bicarbonate levels and slow progression of kidney disease has been embedded in clinical practice guidelines for decades on the basis of animal models and controversial clinical trials. This review will critically appraise the literature base for this recommendation and determine whether the available evidence supports this common practice, which is a timely endeavor considering the impending demotion of metabolic acidosis treatment from recommendation to practice point in forthcoming KDIGO guidelines.Recent findingsEarlier, open-label, studies supporting the utility of sodium bicarbonate therapy to slow progression of chronic kidney disease have been challenged by more recent, blinded, studies failing to show benefit on CKD progression. This was further demonstrated in the absence of concomitant sodium administration with the hydrochloric acid binder veverimer, which failed to demonstrate benefit on renal death, end stage kidney disease or 40% reduction in estimated glomerular filtration rate in a large multicenter trial.SummaryThe current body of literature does not support the routine treatment of metabolic acidosis in patients with CKD and the authors agree with the forthcoming KDIGO guidelines to de-emphasize this common practice.

2024-03-01·Journal of the American Society of Nephrology

VALOR-CKD: A Multicenter, Randomized, Double-Blind Placebo-Controlled Trial Evaluating Veverimer in Slowing Progression of CKD in Patients with Metabolic Acidosis

Article

作者: Stasiv, Yuri ; Parsell, Dawn ; Wheeler, David C ; Perkovic, Vlado ; Inker, Lesley A ; Mathur, Vandana S ; Li, Elizabeth ; Klaerner, Gerrit ; Wesson, Donald E ; Tangri, Navdeep ; Bushinsky, David A ; Walker, Michael

Significance StatementMetabolic acidosis is a common complication of CKD and is associated with more rapid decline of kidney function, but well-powered controlled randomized trials testing the effect of treating metabolic acidosis on slowing CKD progression have not been conducted. The VALOR-CKD study randomized 1480 individuals with CKD and metabolic acidosis, across 320 sites to placebo or veverimer (a novel hydrochloric acid binder). The findings did not demonstrate the efficacy of veverimer in slowing CKD progression, but the difference in serum bicarbonate between placebo and drug arms was only approximately 1 mEq/L. Veverimer was safe and well tolerated.BackgroundMetabolic acidosis is common in CKD, but whether its treatment slows CKD progression is unknown. Veverimer, a novel hydrochloric acid binder that removes acid from the gastrointestinal tract, leads to an increase in serum bicarbonate.MethodsIn a phase 3, double-blind, placebo-controlled trial, patients with CKD (eGFR of 20–40 ml/min per 1.73 m2) and metabolic acidosis (serum bicarbonate of 12–20 mEq/L) from 35 countries were randomized to veverimer or placebo. The primary outcome was the composite end point of CKD progression, defined as the development of ESKD (kidney transplantation or maintenance dialysis), a sustained decline in eGFR of ≥40% from baseline, or death due to kidney failure.ResultsThe mean (±SD) baseline eGFR was 29.2±6.3 ml/min per 1.73 m2, and serum bicarbonate was 17.5±1.4 mEq/L; this increased to 23.4±2.0 mEq/L after the active treatment run-in. After randomized withdrawal, the mean serum bicarbonate was 22.0±3.0 mEq/L and 20.9±3.3 mEq/L in the veverimer and placebo groups at month 3, and this approximately 1 mEq/L difference remained stable for the first 24 months. A primary end point event occurred in 149/741 and 148/739 patients in the veverimer and placebo groups, respectively (hazard ratio, 0.99; 95% confidence interval, 0.8 to 1.2; P = 0.90). Serious and overall adverse event incidence did not differ between the groups.ConclusionsAmong patients with CKD and metabolic acidosis, treatment with veverimer did not slow CKD progression. The lower than expected bicarbonate separation may have hindered the ability to test the hypothesis.Clinical Trial registry name and registration numberVALOR-CKD, NCT03710291.

2023-12-01·Journal of Cachexia, Sarcopenia and Muscle

Effects of correcting metabolic acidosis on muscle mass and functionality in chronic kidney disease: a systematic review and meta‐analysis

Review

作者: Severs, David ; de Roos, Nicole M. ; Olieman, Joanne F. ; de Mik ‐ van Egmond, Anneke M.E. ; Jans, Inez ; Visser, Wesley J. ; van der Hoef, Iris ; Hoorn, Ewout J. ; van der Burgh, Anna C. ; van de Braak, Elma E.M.

AbstractMetabolic acidosis unfavourably influences the nutritional status of patients with non‐dialysis dependent chronic kidney disease (CKD) including the loss of muscle mass and functionality, but the benefits of correction are uncertain. We investigated the effects of correcting metabolic acidosis on nutritional status in patients with CKD in a systematic review and meta‐analysis. A search was conducted in MEDLINE and the Cochrane Library from inception to June 2023. Study selection, bias assessment, and data extraction were independently performed by two reviewers. The Cochrane risk of bias tool was used to assess the quality of individual studies. We applied random effects meta‐analysis to obtain pooled standardized mean difference (SMD) and 95% confidence intervals (CIs). We retrieved data from 12 intervention studies including 1995 patients, with a mean age of 63.7 ± 11.7 years, a mean estimated glomerular filtration rate of 29.8 ± 8.8 mL/min per 1.73 m2, and 58% were male. Eleven studies performed an intervention with oral sodium bicarbonate compared with either placebo or with standard care and one study compared veverimer, an oral HCl‐binding polymer, with placebo. The mean change in serum bicarbonate was +3.6 mEq/L in the intervention group and +0.4 mEq/L in the control group. Correcting metabolic acidosis significantly improved muscle mass assessed by mid‐arm muscle circumference (SMD 0.35 [95% CI 0.16 to 0.54], P < 0.001) and functionality assessed with the sit‐to‐stand test (SMD −0.31 [95% CI −0.52 to 0.11], P = 0.003). We found no statistically significant effects on dietary protein intake, handgrip strength, serum albumin and prealbumin concentrations, and blood urea nitrogen. Correcting metabolic acidosis in patients with CKD improves muscle mass and physical function. Correction of metabolic acidosis should be considered as part of the nutritional care for patients with CKD.

47

项与 Veverimer 相关的新闻（医药）

2025-04-25

·PRNewswire

Renibus Therapeutics Announces Poster Presentation on RBT-1 at the 47th Annual Meeting of the Society of Cardiovascular Anesthesiologists (SCA)

- Renibus recently completed enrollment in a Phase 3 pivotal trial PROTECT to reduce the risk of post-operative complications and improve outcomes following cardiac surgery - SOUTHLAKE, Texas, April 25, 2025 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardiac, renal, and metabolic diseases, today announced that a poster presentation will be delivered on RBT-1 at the 47th Annual Meeting of the Society of Cardiovascular Anesthesiologists (SCA), taking place April 26-29, 2025 in Montreal. RBT-1 is a single-dose, first-in-class, preconditioning agent that is administered intravenously 24-48 hours prior to patients undergoing non-emergent cardiac and/or valve surgery. Renibus previously completed a Phase 2 study of RBT-1 (NCT04564833) in February 2023, announced positive final results from this study in May 2023, and has recently completed enrollment in its Phase 3 PROTECT study. RBT-1 has received Breakthrough and Fast Track Designations from the US FDA. "We are excited to build on our recent momentum of achieving full enrollment in our Phase 3 PROTECT study with a poster presentation at SCA 2025 that we can share with the global anesthesiologist community," stated Jeffrey Keyser, RPh, JD, PhD, President and CEO of Renibus. "Our poster highlights the complicated economic impact of post-operative complications and increasing costs for CABG and value surgery to the healthcare system, which directly affects anesthesiologists. With the use of RBT-1 in our Phase 2 study, we reduced the complication rates from cardiovascular surgery, and in turn, the overall healthcare costs. We look forward to continuing to demonstrate these encouraging results in Phase 3." Frans van Wagenberg, MD, Huntsville Heart Center, Huntsville, Alabama, commented, "I am pleased to present results of a cost-analysis based on a Phase 2 trial which suggest that RBT-1 has a protective effect, leading to lower complication rates and reduced average expected costs overall. Additional data from an ongoing Phase 3 trial, which includes a 1-year post-discharge follow-up, will further evaluate the impact of RBT-1 on clinical, economic, and qualitative outcomes compared to standard care." Details of the poster presentation at SCA 2025: Title: "Clinical and Economic Impact of RBT-1 on Post-operative Complications and Costs for CABG and Valve Surgery" Date and Time: Sunday, April 27, 2025 at 12:30 Authors: Frans van Wagenberg, MD, Lynn Cherry, PhD, Bhupinder Singh, MD, Stacey Ruiz, PhDc, Raf Magar MB About RBT-1 RBT-1 (stannic protoporfin/iron sucrose) is a potent inducer of anti-inflammatory andantioxidant pathways currently being evaluated in the Phase 3 PROTECT study for its lead indication to reduce post-operative complications following cardiothoracic surgery. Previously, Renibus completed the Phase 2 study of RBT-1 (NCT04564833) in February 2023 and announced positive final results from this study in May 2023. In October 2023, Renibus initiated enrollment and administration of RBT-1 in its PROTECT Phase 3 pivotal study and announced completion of enrollment in April 2025. RBT-1 was granted Breakthrough Therapy designation status from the U.S. FDA to reduce the risk of complications in patients undergoing cardiothoracic surgery. About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus' first-in-a-new class lead program is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. It is in a Phase 3 pivotal trial (called PROTECT) to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. The drug has received FDA Breakthrough and Fast Track Designations. Veverimer is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. The drug has received FDA Orphan Drug Designation. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile with a goal of identifying an indication for evaluation in clinical trials. Renibus has three additional assets at earlier stages of development. For more information, please visit the Company's website at and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-914-1962 Business Development Contact Jamie Donadio CFO, Renibus [email protected] SOURCE Renibus Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期快速通道临床2期孤儿药突破性疗法

2025-03-26

·PRNewswire

Renibus to Participate in the 24th Annual Needham Healthcare Virtual Healthcare Conference

SOUTHLAKE, Texas, March 26, 2025 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardiac, renal, and metabolic diseases, today announced its participation in the 24th Annual Needham Virtual Healthcare Conference taking place April 7-10, 2025. This event is being held in a virtual format during which Company management will participate in one-on-one meetings with investors. About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus' first-in-a-new class lead program is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. It is in a Phase 3 pivotal trial to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. The drug has received FDA Breakthrough and Fast Track Designations. Veverimer is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile with a goal of identifying an indication for evaluation in clinical trials. Renibus has three additional assets at earlier stages of development. For more information, please visit the Company's website at and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-914-1962 Business Development Contact Jamie Donadio CFO, Renibus [email protected] SOURCE Renibus Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期快速通道

2025-02-05

·PRNewswire

Renibus to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

SOUTHLAKE, Texas, Feb. 5, 2025 /PRNewswire/ -- Renibus Therapeutics® ("Renibus"), a clinical-stage biopharmaceutical company focusing on the prevention and treatment of cardiac, renal, and metabolic diseases, today announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference, being held February 11-12, 2025, in a virtual format. Jeffrey Keyser, RPh, JD, PhD, President and CEO of Renibus, will present on Wednesday, February 12, 2025, at 10:40 am ET. Company management will also meet with investors in one-on-one meetings during the conference. About Renibus Therapeutics Renibus is a clinical stage biopharmaceutical company dedicated to treating, improving, and extending patients' lives by developing products to prevent disease progression, improve outcomes and protect against organ damage associated with cardio, renal and metabolic diseases. Renibus' first-in-a-new class lead program is RBT-1 (stannic protoporfin / iron sucrose), a single dose IV drug that is given over 1-2 hours, 24-48 hours prior to patients undergoing elective cardiac and/or valve surgery. It is in a Phase 3 pivotal trial to reduce the risk of post operative complications and improve outcomes following cardiothoracic surgery. The drug has received FDA Breakthrough and Fast Track Designations. Veverimer is an oral, non-absorbed hydrochloric acid binder that was acquired from Tricida. We are currently evaluating veverimer in preclinical models and analyzing historical data to further our understanding of its clinical profile with a goal of identifying an indication for evaluation in clinical trials. Renibus has three additional assets at earlier stages of development. For more information, please visit the Company's website at and engage with us on LinkedIn. Investor and Media Contact: Amy Conrad Juniper Point [email protected] 858-914-1962 Business Development Contact Jamie Donadio CFO, Renibus [email protected] SOURCE Renibus Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期快速通道并购

100 项与 Veverimer 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
酸中毒	临床2期	美国	Tricida, Inc.	2019-09-04
慢性肾病	临床2期	保加利亚	Tricida, Inc.	2017-09-26
慢性肾病	临床2期	美国	Tricida, Inc.	2017-09-26
慢性肾病	临床2期	格鲁吉亚	Tricida, Inc.	2017-09-26
慢性肾病	临床2期	乌克兰	Tricida, Inc.	2017-09-26
慢性肾病	临床2期	克罗地亚	Tricida, Inc.	2017-09-26
慢性肾病	临床前	克罗地亚	Tricida, Inc.	2017-09-26
慢性肾病	临床前	格鲁吉亚	Tricida, Inc.	2017-09-26
慢性肾病	临床前	美国	Tricida, Inc.	2017-09-26
慢性肾病	临床前	保加利亚	Tricida, Inc.	2017-09-26

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03390842 (Pubmed) 人工标引	临床3期	酸中毒 \| 慢性肾病	77	Veverimer	觸積艱積鹹獵繭夢艱遞(蓋構醖襯積糧鹽蓋簾齋): P-Value = 0.0002 更多	积极	2022-02-25
				Placebo
NCT03390842 (CTgov)	临床3期	慢性肾病	196	TRC101 (TRC101 Treatment Arm)	簾廠顧衊衊鹹鏇鏇餘膚(築醖鹽築餘簾膚淵糧願) = 壓齋範遞顧簾遞鏇廠憲窪範積網廠鏇夢築鬱壓 (蓋夢夢淵夢醖壓醖鹹鹹, 鬱積鑰繭壓築範製餘顧 ~ 艱遞鬱範遞獵鑰膚鑰鹽) 更多	-	2021-10-22
				Placebo (Placebo Treatment Arm)	簾廠顧衊衊鹹鏇鏇餘膚(築醖鹽築餘簾膚淵糧願) = 襯鏇鬱鏇襯餘醖窪襯築窪範積網廠鏇夢築鬱壓 (蓋夢夢淵夢醖壓醖鹹鹹, 艱構遞膚範醖獵廠遞鬱 ~ 糧範醖鹽積觸製鹹艱齋) 更多
NCT03317444 (CTgov)	临床3期	慢性肾病	217	TRC101 (TRC101 Treatment Arm)	蓋獵願願鹹鑰範鏇構簾(顧壓製鹽餘築願醖膚夢) = 顧廠廠襯遞願願構壓構餘夢鏇範選蓋醖遞鏇壓 (衊鹽築遞構衊鑰遞範獵, 壓襯鑰鹹範夢餘鬱選顧 ~ 醖網艱積遞築齋蓋構淵) 更多	-	2021-04-26
				Placebo (Placebo Treatment Arm)	蓋獵願願鹹鑰範鏇構簾(顧壓製鹽餘築願醖膚夢) = 獵襯廠壓鑰網構積獵選餘夢鏇範選蓋醖遞鏇壓 (衊鹽築遞構衊鑰遞範獵, 壓積廠鏇選築夢積廠鏇 ~ 構繭鏇構範遞蓋鹽繭積) 更多
ASN2020	临床3期	-	217	Veverimer	憲襯糧觸範顧齋窪窪餘(願範鹹簾衊願襯顧鬱壓) = improved both KDQOL-PFD scores and RCS time 繭觸鹽願簾衊觸膚艱餘 (選淵憲鬱遞糧構鑰鹹構 ) 更多	积极	2020-10-19
ASN2020	临床3期	慢性肾病	217	Veverimer	壓艱遞齋範範觸鬱選簾(鏇獵築繭顧鏇艱觸壓窪) = 顧衊鹹糧鹽醖壓選獵蓋醖築壓繭繭蓋鬱繭鏇鑰 (淵蓋膚衊選淵獵獵艱鏇 )	积极	2020-10-19
ASN2020	临床3期	酸中毒 \| 慢性肾病	193	Veverimer	觸糧積製範鏇範遞積積(獵鏇壓餘製衊淵築鏇餘) = 願糧膚壓鹹獵遞願鑰壓獵艱醖築齋齋簾鬱繭夢 (構構蓋艱窪鑰繭廠淵衊 )	积极	2020-10-19
TRCA-301E (ASN2020)	临床3期	糖尿病 \| 慢性肾病	196	Veverimer	餘鹽鏇獵顧鑰製醖製夢(鹽網鏇觸顧糧廠鑰觸鬱) = significantly improved in the veverimer group (+12.5 v +0.3, P <0.001) 鬱鏇餘積製願觸構鹽積 (鹽繭鹹簾蓋願觸膚蓋觸 )	积极	2020-10-19
ASN2020	临床1期	-	46	Veverimer	繭醖鹹蓋憲製願壓膚餘(獵鬱築襯網觸積網鹽鏇) = 壓構顧糧選顧艱顧製鏇廠艱構範艱積鬱觸膚膚 (鬱廠範願蓋觸觸醖觸夢 )	积极	2020-10-19
				Omeprazole	繭醖鹹蓋憲製願壓膚餘(獵鬱築襯網觸積網鹽鏇) = 獵積窪壓鏇膚壓顧鏇繭廠艱構範艱積鬱觸膚膚 (鬱廠範願蓋觸觸醖觸夢 )
ASN2020	N/A	-	-	Veverimer	蓋餘餘齋窪衊襯網襯製(鏇築範鹹鏇範觸顧顧壓) = 選蓋蓋鑰築夢願憲廠艱觸窪觸網遞獵鬱糧顧膚 (壓鏇簾憲網鹽築顧積蓋 )	积极	2020-10-19
TRCA-301E (ERA2020)	临床3期	慢性肾病	196	Veverimer	簾襯願築艱蓋醖廠艱鹽(願觸鹽餘製醖觸鏇壓糧) = 願顧範鏇淵顧觸遞窪鏇簾廠醖願夢遞艱鏇襯網 (衊範齋顧蓋鏇衊願鹽簾 ) 更多	积极	2020-06-06
				Placebo	簾襯願築艱蓋醖廠艱鹽(願觸鹽餘製醖觸鏇壓糧) = 獵繭蓋膚廠鑰願鏇壓艱簾廠醖願夢遞艱鏇襯網 (衊範齋顧蓋鏇衊願鹽簾 )